HUP9904116A2 - Citokróm P450-et transzdukáló retrovirális vektorok - Google Patents

Citokróm P450-et transzdukáló retrovirális vektorok

Info

Publication number
HUP9904116A2
HUP9904116A2 HU9904116A HUP9904116A HUP9904116A2 HU P9904116 A2 HUP9904116 A2 HU P9904116A2 HU 9904116 A HU9904116 A HU 9904116A HU P9904116 A HUP9904116 A HU P9904116A HU P9904116 A2 HUP9904116 A2 HU P9904116A2
Authority
HU
Hungary
Prior art keywords
retroviral vectors
cytochrome
subject
promotors
cancer
Prior art date
Application number
HU9904116A
Other languages
English (en)
Inventor
Walter H. Günzburg
Peter Karle
Robert Michael Saller
Original Assignee
Bavarian Nordic Research Institute A/S
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9904116(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Research Institute A/S, GSF-Forschungszentrum für Umwelt und Gesundheit GmbH. filed Critical Bavarian Nordic Research Institute A/S
Publication of HUP9904116A2 publication Critical patent/HUP9904116A2/hu
Publication of HUP9904116A3 publication Critical patent/HUP9904116A3/hu
Publication of HU221349B1 publication Critical patent/HU221349B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

A találmány tárgyát célsejtspecifikűs szabályőzóelemek vagy prőmóterekés/vagy röntgensűgárzással indűkálható prőmóterek szabályzása alattálló citőkróm P450 gént kódőló, replikációdefektív retrővirálisvektőrők képezik, amelyek alkalmasak ártalmatlan rák prődrőgőkcitőtőxikűs metabőlitőkká történő átalakítására. A találmány tárgyátképezik tővábbá a találmány szerinti vektőrőkat hőrdőzó sejtekettartalmazó kapszűlák, valamint a találmány szerinti retrővirálisvektőrők alkalmazásai különféle rákők kezelésére, ill. daganatőkeltávőlítására szőlgáló gyógyászati készítmények éskészítménykészletek előállítására. A találmány szerinti megőldásalkalmas rák kezelésére biztőnságős, citőkróm P450 gént célbajűttatniés expresszáltatni képes retrővirális vektőrők alkalmazásával. ŕ
HU9904116A 1996-03-27 1997-03-27 Capsules for microencapsulating cells which able to express cytochrome p 450 HU221349B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK35296 1996-03-27
PCT/EP1997/001585 WO1997035994A2 (en) 1996-03-27 1997-03-27 Cytochrome p450 transducing retroviral vectors

Publications (3)

Publication Number Publication Date
HUP9904116A2 true HUP9904116A2 (hu) 2000-04-28
HUP9904116A3 HUP9904116A3 (en) 2001-01-29
HU221349B1 HU221349B1 (en) 2002-09-28

Family

ID=8092560

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904116A HU221349B1 (en) 1996-03-27 1997-03-27 Capsules for microencapsulating cells which able to express cytochrome p 450

Country Status (19)

Country Link
US (1) US6893634B1 (hu)
EP (1) EP0892852B1 (hu)
JP (1) JP4229982B2 (hu)
AT (1) ATE309383T1 (hu)
AU (1) AU713382B2 (hu)
CA (1) CA2250173A1 (hu)
CZ (1) CZ288074B6 (hu)
DE (1) DE69730595D1 (hu)
DK (1) DK0892852T3 (hu)
ES (1) ES2253775T3 (hu)
HU (1) HU221349B1 (hu)
IL (1) IL125795A0 (hu)
NO (1) NO325392B1 (hu)
NZ (1) NZ331765A (hu)
PL (1) PL188323B1 (hu)
RU (2) RU2223788C2 (hu)
SI (1) SI0892852T1 (hu)
SK (1) SK282744B6 (hu)
WO (1) WO1997035994A2 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286979B6 (en) 1995-06-27 2000-08-16 Bavarian Nordic Res Inst As Capsule encapsulating cells producing viral particles, process of its preparation and pharmaceutical preparation for gene therapy
PL188323B1 (pl) 1996-03-27 2005-01-31 Bavarian Nordic As Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
JP2002526510A (ja) * 1998-09-21 2002-08-20 トランジェーヌ、ソシエテ、アノニム 薬剤またはプロドラッグを必要とする患者の予備治療のための医薬組成物
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
DE69932261D1 (de) * 1999-01-04 2006-08-17 Innovata Plc Ruddington P450 / acetaminophen gdept zur krebsbehandlung
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
AU2002336162A1 (en) * 2001-09-21 2003-04-01 Oxford Biomedica (Uk) Limited Pseudotyped retroviral vector system
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
MX2015006813A (es) 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335798C (en) 1988-05-17 1995-06-06 Sloan Kettering Institute For Cancer Research Retroviral vector
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
CN1117156C (zh) 1994-09-02 2003-08-06 Gsf环境与健康研究中心有限公司 非自动失活的定位表达的逆转录病毒载体
CZ286979B6 (en) 1995-06-27 2000-08-16 Bavarian Nordic Res Inst As Capsule encapsulating cells producing viral particles, process of its preparation and pharmaceutical preparation for gene therapy
ATE214101T1 (de) * 1995-09-06 2002-03-15 Austrian Nordic Biotherapeutic Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
PL188323B1 (pl) 1996-03-27 2005-01-31 Bavarian Nordic As Kapsuła zawierająca komórki i jej zastosowanie oraz kompozycja i środek farmaceutyczny

Also Published As

Publication number Publication date
NO984540L (no) 1998-09-28
CZ305098A3 (cs) 1999-01-13
RU2185821C2 (ru) 2002-07-27
US6893634B1 (en) 2005-05-17
IL125795A0 (en) 1999-04-11
WO1997035994A2 (en) 1997-10-02
SK132398A3 (en) 1999-04-13
HU221349B1 (en) 2002-09-28
ES2253775T3 (es) 2006-06-01
CA2250173A1 (en) 1997-10-02
AU2382797A (en) 1997-10-17
DK0892852T3 (da) 2006-03-06
EP0892852A2 (en) 1999-01-27
CZ288074B6 (cs) 2001-04-11
NO984540D0 (no) 1998-09-28
EP0892852B1 (en) 2005-11-09
SI0892852T1 (sl) 2006-04-30
ATE309383T1 (de) 2005-11-15
JP2000509249A (ja) 2000-07-25
PL329071A1 (en) 1999-03-15
JP4229982B2 (ja) 2009-02-25
SK282744B6 (sk) 2002-12-03
NO325392B1 (no) 2008-04-21
WO1997035994A3 (en) 1997-11-20
AU713382B2 (en) 1999-12-02
RU2223788C2 (ru) 2004-02-20
DE69730595D1 (de) 2004-10-14
HUP9904116A3 (en) 2001-01-29
PL188323B1 (pl) 2005-01-31
NZ331765A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
HUP9904116A2 (hu) Citokróm P450-et transzdukáló retrovirális vektorok
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
EP1312679B8 (en) Recombinant MVA virus, and the use thereof
EP0584266A4 (en) KARCINOEMBRYONAL ANTIGENT EXPECTING RECOMBINANT VIRUSES AND METHODS OF USE.
FI881185A0 (fi) Human mangan-superoxiddismutas (hmn-sod).
HUP0003745A2 (hu) Eljárások és készítmények tumorspecifikus citotoxicitás indukálására
GR3035447T3 (en) Parenteral busulfan for treatment of malignant disease
NO980218L (no) p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling
HUP9900905A2 (hu) D4-Vitamin származékok alkalmazása rák kezelésére szolgáló gyógyászati készítmények előállítására
Loimas et al. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase–mediated suicide gene therapy
HUP0004326A2 (hu) A tumor-szupresszor génterápia és a kemoterápia kombinálása a daganatok kezelésében
DE69434244D1 (de) Verbesserte krebstherapie
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
EP1190040A4 (en) HERPES-SIMPLEX VIRUS, EXPRESSING FOREIGN GENES, AND A METHOD TO TREAT CANCER THEREFOR
PL324289A1 (en) Encapsulated cells producing virus particles
EP0689586B8 (en) Vpr function and activity
HUP9800574A2 (hu) A cdc25B-gén promótere, előállítása és alkalmazása
Freeman Suicide gene therapy
MXPA04003732A (es) Metodos y composiciones para inducir la citotoxicidad especifica de los tumores.
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees